restor3D, recognized as a pioneer in personalized orthopedic technology, has announced a significant strategic investment partnership with Partners Group, a leading private market investment firm. Under this agreement, Partners Group will acquire a notable minority stake in restor3d, representing the company’s introduction to institutional investment. The deal involves a total capital raise of $104 million, including $65 million in new equity from Partners Group and $39 million from existing shareholders.
Founded in 2017, restor3d utilizes proprietary AI-driven design software, advanced additive manufacturing, and rapid surgical planning to create implants precisely tailored to both the surgeon’s preferences and the individual patient’s anatomy. The company has developed FDA-cleared solutions for procedures involving the shoulder, hip, knee, foot, and ankle. In 2024 alone, restor3d worked with over 520 surgeons across 740 hospitals nationwide, underscoring its growing influence and adoption.
The new funds will accelerate restor3d’s commitment to product innovation, commercial expansion, and increased accessibility to personalized orthopedic care. Partners Group will join restor3d’s board of directors, bringing substantial operational and healthcare expertise to help steer the company’s long-term strategy and growth trajectory.
This collaboration marks a critical milestone for restor3d, further strengthening its mission to transform musculoskeletal care. The company is dedicated to expanding its portfolio of personalized orthopedic solutions, advancing digital surgical planning technologies, and broadening its reach into new and existing markets. As more surgeons embrace restor3d’s innovative, data-backed approach, the company is poised to drive significant improvements in patient outcomes and reimagine the future of orthopedic treatment through continuous innovation and personalization.
This partnership sets the stage for restor3d to continue leading the way in delivering cutting-edge, patient-specific musculoskeletal implants and solutions worldwide.
KEY QUOTES:
“This investment marks an exciting milestone for restor3d as we expand access to personalized orthopedic solutions. With Partners Group’s support, we will continue to deliver innovations that empower surgeons and improve outcomes for patients across the full spectrum of joint replacement.”
Kurt Jacobus, CEO of restor3d
“restor3d is solving a key issue in the orthopedic market, namely that procedures have often relied on off-the-shelf products that cannot accommodate different patient anatomies. restor3d addresses this challenge by delivering rapid, precise patient-specific implants that lead to better surgical fit and function, ultimately improving patient outcomes.”
Ashley Torres, Member of Management, Private Equity, Partners Group
“We think restor3d’s offering is set to benefit from several thematic trends, including aging demographics and rising engagement in sports and recreational activities in the US. We look forward to working with the Company’s highly experienced management team.”
Todd Miller, Partner, Head Private Equity Health & Life, Partners Group
